There Is a Differential Pattern in the Fatty Acid Profile in Children with CD Compared to Children with UC

Kikut, Justyna; Drozd, Arleta; Mokrzycka, Małgorzata; Grzybowska-Chłebowczyk, Urszula; Ziętek, Maciej

doi:10.3390/jcm11092365

Cited by 4 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have also shown a higher activity of 5-LOX in patients compared to the healthy control group. 5-HETE is a strong activator of neutrophilia [8,38]. These results are consistent with a study conducted by Masoodi and others.…”

Section: Discussionsupporting

confidence: 92%

Calprotectin Is Associated with HETE and HODE Acids in Inflammatory Bowel Diseases

Szczuko,

Komisarska,

Kikut

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Background: Intestinal diseases are identified as autoimmune phenomena attributed to a specific virus that binds to the mucosal epithelium. The importance of precise diagnostic processes and identification is emphasized, but the multifaceted and complex etiological factors pose challenges for effective treatment. A recent supplementary study suggested a linkage between the secretion of calprotectin, a protein associated with inflammatory processes, and increased levels of hydroxyeicosatrienoic acids (HETE) and hydroxyoctadecadienoic (HODE) compounds. Methods: Sixty-two patients (average age: 14.06 ± 2.93 years) suffering from inflammatory bowel diseases were included in this study. Comparative analyses were performed to assess the concentrations of calprotectin against the levels of arachidonic acid derivatives. The calprotectin concentration was determined using the enzyme-linked immunosorbent assay (ELISA) method. The derivatives of HETE and HODE were identified through liquid chromatography. Results: Patients with Crohn’s disease (CD) displayed higher average concentrations of fatty acid metabolites; however, no correlation with calprotectin was observed. A dependency of 12S HETE concentration relative to age was noted in the CD group, and a similar trend was also identified in ulcerative colitis (UC), with the significant metabolites being 15 HETE and 5 oxoETE. In UC patients, a positive correlation was established between the calprotectin concentration and the acids 5-HETE and 12-HETE. Conclusions: These findings may be instrumental for monitoring the inflammatory states of patients and indicating a pathway for intervention. The metabolite 16RS HETE is associated with UC activity, and 15-HETE is related to the disease’s duration. A relatively more significant role of HETE acids in the progression of the disease was observed in UC.

show abstract

Section: Discussionsupporting

confidence: 92%

Calprotectin Is Associated with HETE and HODE Acids in Inflammatory Bowel Diseases

Szczuko,

Komisarska,

Kikut

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Kikut та співавт. також показали, що пальмітинова кислота, визначена в плазмі крові підлітків, пов'язана зі стадією ремісії при ХК, тоді як лінолева кислота -з активною фазою цього захворювання [21]. Barnes Патологія кишечника / Bowel Pathology високе споживання з їжею жирних кислот, включно з міристиновою кислотою, з підвищеним ризиком розвитку НВК [22].…”

Section: вступunclassified

“…Патологія кишечника / Bowel Pathology вати активацію нуклеарного фактора транскрипції κB (НФ-κB) та ІЛ-8. Ще лауринова кислота може бути антагоністом імунної системи, стимулюючи білок толподібного рецептора 4 (ТПР-4) та утворюючи монолаурин у кишечнику, який, у свою чергу, має антимікробну дію [21].…”

Section: примітки: вірогідна різниця порівняно з контролем: *** -P < ...unclassified

“…Є припущення, що цьому можуть сприяти зміни мікробіоти кишечника. Це вказує на ризик підвищення кишкової проникності у пацієнтів із ЗЗК [21,26]. Також нами було встановлено статистично значуще підвищення вмісту стеаринової кислоти в сироватці крові при ЗЗК, особливо в І групі пацієнтів, яка здатна пригнічувати ріст ендотеліальних клітин кишечника, а також індукувати запалення, апоптоз та посилювати експресію молекули міжклітинної адгезії-1 у кишечнику [27].…”

Section: примітки: вірогідна різниця порівняно з контролем: *** -P < ...unclassified

See 1 more Smart Citation

Prognostic value of blood saturated fatty acids in inflammatory bowel diseases

Stoykevich

Karachynova

Кленіна

et al. 2023

GASTRO

View full text Add to dashboard Cite

Background. Pathogenetic factors that cause the development of inflammatory bowel diseases (IBD) remain poorly understood, namely, the peculiarities of saturated fatty acids (SFAs) in the blood serum at different degrees of disease severity, which is quite an important task. Objective: to evaluate serum level of SFAs depending on IBD severity. Materials and methods. Thirty-seven patients with IBD were examined, their average age was (38.5 ± 2.1) years. Depending on the severity of the disease, the patients were divided into 2 groups: group I — with IBD of moderate severity (n = 24) and group II — with severe IBD (n = 13). The control group consisted of 16 healthy people. The quantitative content of SFAs in the blood serum of the examined patients was determined by gas chromatography. Median (Me), lower (25%) and upper (75%) quartiles were used to describe the data. Results. Biochemical analysis revealed a tendency to decrease in the level of short-chain SFA (butyric acid; p > 0.05) and a significant increase in the total content of medium- and long-chain SFAs (MCSFAs and LCSFAs; p < 0.001) in the serum of group I and II patients compared to the controls. It was found that with increasing severity of IBD, there was a decrease in LCSFAs content in the blood (r = –0.420, p = 0.048). The serum spectrum of SFAs was analyzed and a significant increase in all MCSFAs fractions was detected in both groups of patients: caproic acid (p < 0.001), caprylic acid (p < 0.001), capric acid (p ≤ 0.002), undecylic acid (p ≤ 0.006) and lauric acid (p ≤ 0.001). Characteristically, the content of the most MCSFAs fractions had a tendency to decrease (p > 0.05) in group I against group II of patients. The content of LCSFAs, namely: tridecylic acid (p ≤ 0.012), myristic acid (p < 0.001), pentadecylic acid (p ≤ 0.012), palmitic acid (p < 0.001), stearic acid (p ≤ 0.001) and heneicosylic acid (p < 0.001), increased significantly in group I and II of patients, while the content of margaric and eicosanoic acids — only in group I compared to the controls. Almost all LCSFAs (except tridecylic acid) had a tendency to increase in group I against group II. Conclusions. It has been shown that the content of SFAs in the blood depends on the degree of IBD severity. The mechanism of SFAs action with different carbon chain lengths is multidirectional and is associated with the effect on pro-/anti-inflammatory mediators and with the maintenance of the immune and intestinal homeostasis. The necessity of determining serum SFAs in IBD to correct the identified disorders has been confirmed.

show abstract

“…MCFAs such as heptanoate, octanoate and nonanoate, exhibit markedly decreased levels in IBD patients ( 134 ). In pediatric patients, there were variations of lauric acid between CD and UC, and higher levels of lauric acid were observed during UC active phases compared to remission ( 135 ). In summary, reduced levels of MCFAs are common among IBD patients, and proportions of MCFAs differ between CD and UC.…”

Section: Medium-chain Fatty Acidsmentioning

confidence: 99%

Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment

Yan,

Ye,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract. Though the pathogenesis of IBD remains unclear, diet is increasingly recognized as a pivotal factor influencing its onset and progression. Fatty acids, essential components of dietary lipids, play diverse roles in IBD, ranging from anti-inflammatory and immune-regulatory functions to gut-microbiota modulation and barrier maintenance. Short-chain fatty acids (SCFAs), products of indigestible dietary fiber fermentation by gut microbiota, have strong anti-inflammatory properties and are seen as key protective factors against IBD. Among long-chain fatty acids, saturated fatty acids, trans fatty acids, and ω-6 polyunsaturated fatty acids exhibit pro-inflammatory effects, while oleic acid and ω-3 polyunsaturated fatty acids display anti-inflammatory actions. Lipid mediators derived from polyunsaturated fatty acids serve as bioactive molecules, influencing immune cell functions and offering both pro-inflammatory and anti-inflammatory benefits. Recent research has also highlighted the potential of medium- and very long-chain fatty acids in modulating inflammation, mucosal barriers, and gut microbiota in IBD. Given these insights, dietary intervention and supplementation with short-chain fatty acids are emerging as potential therapeutic strategies for IBD. This review elucidates the impact of various fatty acids and lipid mediators on IBD and delves into potential therapeutic avenues stemming from these compounds.

show abstract

There Is a Differential Pattern in the Fatty Acid Profile in Children with CD Compared to Children with UC

Cited by 4 publications

References 41 publications

Calprotectin Is Associated with HETE and HODE Acids in Inflammatory Bowel Diseases

Calprotectin Is Associated with HETE and HODE Acids in Inflammatory Bowel Diseases

Prognostic value of blood saturated fatty acids in inflammatory bowel diseases

Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment

Contact Info

Product

Resources

About